ISPE and PDA have performed a detailed analysis of their two key initiatives ‘PQLI’ and ‘PCMO’ in order to ensure coordination and prevent unnecessary duplication. As a result, program leaders have determined that there is no significant overlap between the efforts of each organization. In those cases where overlap has been identified, agreement was reached to realign the scope and to work together to avoid any duplication of effort.
In summary, both ISPE and PDA have agreed that the PQLI and PCMO deliverables are:
With this in mind, we are determined to utilize the expertise of two organizations to find practical approaches for the changing pharmaceutical environment according to the new paradigm laid down in ICH Q8 (Q11), Q9 and Q10.
Are You Ready for an FDA Audit of Your Downstream Process?
Thursday, 27 Apr 2017 08.04
Meet PT Kalbio Global Medika – 2017 FOYA Honorable Mention Winner
Wednesday, 26 Apr 2017 09.04
Maximize Your Professional Development at These Signature Events
Tuesday, 25 Apr 2017 12.04